Sandra Hurtado

ORCID: 0000-0001-5640-6796 · 3 papers in corpus
article 2021
Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
F&S reports ·doi:10.1016/j.xfre.2021.05.004

OBJECTIVE: To determine if coexisting adenomyosis limits the efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in reducing heavy menstrual bleeding in women with uterine fibroids. DESIGN…

article 2019
Effect of fibroid location and size on efficacy of elagolix: results from phase 3 clinical trials
·doi:10.1016/j.fertnstert.2019.07.344
article 2019
Effect of Fibroid Location and Size on Efficacy of Elagolix: Results from Phase 3 Clinical Trials
·doi:10.1016/j.jmig.2019.09.666